Pancreatic Cancer Organoids for Biology and Medicine

NCI Center for Cancer Research Eminent Lecture Series David Tuveson is the Roy J. Zuckerberg Professor of Cancer Research, and Deputy Director of the cancer center at Cold Spring Harbor Laboratory (CSHL). Dr. Tuveson obtained a Bachelor ’ s degree in chemistry at M.I.T., followed by M.D. and Ph.D. degrees at Johns Hopkins University. Dr. Tuveson was a medical resident at Brigham and Women ’ s Hospital and a medical oncology fellow at Dana-Farber/Partners Cancer Care. During his post-doctoral years in Boston, Dr. Tuveson co-developed KIT inhibitors for gastrointestinal stromal tumors with Dr. George Demetri. Simultaneously, he generated several widely-used mouse cancer models with Dr. Tyler Jacks. As an independent investigator, his lab generated the first mouse models of ductal pancreatic cancer at the University of Pennsylvania. Subsequently, Dr. Tuveson was recruited to the University of Cambridge to develop preclinical and clinical therapeutic strategies for pancreatic cancer. In Cambridge, his lab identified a variety of parameters that limit therapeutic efficacy in pancreatic cancer, including poor drug delivery and survival factors in the microenvironment. These findings are currently undergoing clinical evaluation. Dr. Tuveson was recruited back to the USA to direct the Cancer Therapeutics Initiative at CSHL and to serve as Director of Research for the Lustgarten Foundation. He continues to practice medical oncology with an adjunct appointment at Memorial Sloan Ke...
Source: Videocast - All Events - Category: Journals (General) Tags: Upcoming Events Source Type: video